Skip to main content
Erschienen in: Inflammation 4/2014

01.08.2014

Association of Interleukin 1 Family with Systemic Sclerosis

verfasst von: Li Zhang, Jun-Wei Yan, Yu-Jie Wang, Ya-Nan Wan, Bing-Xiang Wang, Jin-Hui Tao, Bing Chen, Bao-Zhu Li, Guo-Jun Yang, Jing Wang

Erschienen in: Inflammation | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Systemic sclerosis is a connective tissue disease characterized with fibrosis of skin and/or internal organs, and its specific pathological mechanism remains incompletely understood. IL-1 family, whose biological properties are typically pro-inflammatory and pro-fibrosis, has been associated with systemic sclerosis (SSc). Interleukin (IL)-1 family has 11 members, IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-36Ra, IL-37, and IL-38. With the exception of IL-1Ra and IL-36Ra, each member has its own receptor signal. Abnormal expression of IL-1 and its potential role in the fibrosis process have been probed earliest, as well as its gene polymorphisms with SSc. IL-33 and IL-18 have also been discussed in the recent years, and IL-33 may contribute to the fibrosis of SSc, while IL-18 remains to be researched to confirm its role in fibrosis process. There is a lack of studies on the association of the other members of the IL-1 family, which might provide us the future study area; much more efforts need to be put on this matter.
Literatur
1.
Zurück zum Zitat Wollheim, F.A. 2005. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 44: 1212–1216.CrossRef Wollheim, F.A. 2005. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 44: 1212–1216.CrossRef
2.
Zurück zum Zitat van den Hoogen, F., D. Khanna, J. Fransen, et al. 2013. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/european league against rheumatism collaborative initiative. Arthritis and Rheumatism 65: 2737–2747.PubMedCrossRef van den Hoogen, F., D. Khanna, J. Fransen, et al. 2013. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/european league against rheumatism collaborative initiative. Arthritis and Rheumatism 65: 2737–2747.PubMedCrossRef
3.
Zurück zum Zitat Nikpour, M., W.M. Stevens, A.L. Herrick, et al. 2010. Epidemiology of systemic sclerosis. Best Practice & Research. Clinical Rheumatology 24: 857–869.CrossRef Nikpour, M., W.M. Stevens, A.L. Herrick, et al. 2010. Epidemiology of systemic sclerosis. Best Practice & Research. Clinical Rheumatology 24: 857–869.CrossRef
4.
Zurück zum Zitat van de Veerdonk, F.L., and M.G. Netea. 2013. New insights in the immunobiology of IL-1 family members. Frontiers in Immunology 4: 167.PubMedCentralPubMed van de Veerdonk, F.L., and M.G. Netea. 2013. New insights in the immunobiology of IL-1 family members. Frontiers in Immunology 4: 167.PubMedCentralPubMed
5.
Zurück zum Zitat Dinarello, C.A. 2013. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol 25: 389–393.PubMedCrossRef Dinarello, C.A. 2013. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol 25: 389–393.PubMedCrossRef
6.
Zurück zum Zitat van de Veerdonk, F.L., A.K. Stoeckman, G. Wu, et al. 2012. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America 109: 3001–3005.PubMedCentralPubMedCrossRef van de Veerdonk, F.L., A.K. Stoeckman, G. Wu, et al. 2012. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America 109: 3001–3005.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Boraschi, D., and A. Tagliabue. 2013. The interleukin-1 receptor family. Semin Immunol (13)00115-2. Boraschi, D., and A. Tagliabue. 2013. The interleukin-1 receptor family. Semin Immunol (13)00115-2.
8.
Zurück zum Zitat Alcocer-Varela, J., E. Martinez-Cordero, and D. Alarcon-Segovia. 1985. Spontaneous production of, and defective response to, interleukin-1 by peripheral blood mononuclear cells from patients with scleroderma. Clinical and Experimental Immunology 59: 666–672.PubMedCentralPubMed Alcocer-Varela, J., E. Martinez-Cordero, and D. Alarcon-Segovia. 1985. Spontaneous production of, and defective response to, interleukin-1 by peripheral blood mononuclear cells from patients with scleroderma. Clinical and Experimental Immunology 59: 666–672.PubMedCentralPubMed
9.
Zurück zum Zitat Whicher, J.T., A.M. Gilbert, C. Westacott, et al. 1986. Defective production of leucocytic endogenous mediator (interleukin 1) by peripheral blood leucocytes of patients with systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and mixed connective tissue disease. Clinical and Experimental Immunology 65: 80–89.PubMedCentralPubMed Whicher, J.T., A.M. Gilbert, C. Westacott, et al. 1986. Defective production of leucocytic endogenous mediator (interleukin 1) by peripheral blood leucocytes of patients with systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and mixed connective tissue disease. Clinical and Experimental Immunology 65: 80–89.PubMedCentralPubMed
10.
Zurück zum Zitat Sandborg, C.I., M.A. Berman, B.S. Andrews, et al. 1985. Interleukin-1 production by mononuclear cells from patients with scleroderma. Clinical and Experimental Immunology 60: 294–302.PubMedCentralPubMed Sandborg, C.I., M.A. Berman, B.S. Andrews, et al. 1985. Interleukin-1 production by mononuclear cells from patients with scleroderma. Clinical and Experimental Immunology 60: 294–302.PubMedCentralPubMed
11.
Zurück zum Zitat Berman, M.A., C.I. Sandborg, B.S. Calabia, et al. 1986. Studies of an interleukin 1 inhibitor: characterization and clinical significance. Clinical and Experimental Immunology 64: 136–145.PubMedCentralPubMed Berman, M.A., C.I. Sandborg, B.S. Calabia, et al. 1986. Studies of an interleukin 1 inhibitor: characterization and clinical significance. Clinical and Experimental Immunology 64: 136–145.PubMedCentralPubMed
12.
Zurück zum Zitat Sandborg, C.I., M.A. Berman, B.S. Andrews, et al. 1986. Increased production of an interleukin 1 (IL-1) inhibitor with fibroblast stimulating activity by mononuclear cells from patients with scleroderma. Clinical and Experimental Immunology 66: 312–319.PubMedCentralPubMed Sandborg, C.I., M.A. Berman, B.S. Andrews, et al. 1986. Increased production of an interleukin 1 (IL-1) inhibitor with fibroblast stimulating activity by mononuclear cells from patients with scleroderma. Clinical and Experimental Immunology 66: 312–319.PubMedCentralPubMed
13.
Zurück zum Zitat Umehara, H., S. Kumagai, M. Murakami, et al. 1990. Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. Arthritis and Rheumatism 33: 893–897.PubMedCrossRef Umehara, H., S. Kumagai, M. Murakami, et al. 1990. Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. Arthritis and Rheumatism 33: 893–897.PubMedCrossRef
14.
Zurück zum Zitat Aotsuka, S., K. Nakamura, T. Nakano, et al. 1991. Production of intracellular and extracellular interleukin-1 alpha and interleukin-1 beta by peripheral blood monocytes from patients with connective tissue diseases. Annals of the Rheumatic Diseases 50: 27–31.PubMedCentralPubMedCrossRef Aotsuka, S., K. Nakamura, T. Nakano, et al. 1991. Production of intracellular and extracellular interleukin-1 alpha and interleukin-1 beta by peripheral blood monocytes from patients with connective tissue diseases. Annals of the Rheumatic Diseases 50: 27–31.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Kawaguchi, Y., M. Harigai, M. Hara, et al. 1992. Increased interleukin 1 receptor, type I, at messenger RNA and protein level in skin fibroblasts from patients with systemic sclerosis. Biochemical and Biophysical Research Communications 184: 1504–1510.PubMedCrossRef Kawaguchi, Y., M. Harigai, M. Hara, et al. 1992. Increased interleukin 1 receptor, type I, at messenger RNA and protein level in skin fibroblasts from patients with systemic sclerosis. Biochemical and Biophysical Research Communications 184: 1504–1510.PubMedCrossRef
16.
Zurück zum Zitat Kawaguchi, Y., M. Harigai, K. Suzuki, et al. 1993. Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1 beta. Biochemical and Biophysical Research Communications 190: 154–161.PubMedCrossRef Kawaguchi, Y., M. Harigai, K. Suzuki, et al. 1993. Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1 beta. Biochemical and Biophysical Research Communications 190: 154–161.PubMedCrossRef
17.
Zurück zum Zitat Kawaguchi, Y. 1994. IL-1 alpha gene expression and protein production by fibroblasts from patients with systemic sclerosis. Clinical and Experimental Immunology 97: 445–450.PubMedCentralPubMedCrossRef Kawaguchi, Y. 1994. IL-1 alpha gene expression and protein production by fibroblasts from patients with systemic sclerosis. Clinical and Experimental Immunology 97: 445–450.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Duan, H., J. Fleming, D.K. Pritchard, et al. 2008. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis and Rheumatism 58: 1465–1474.PubMedCrossRef Duan, H., J. Fleming, D.K. Pritchard, et al. 2008. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis and Rheumatism 58: 1465–1474.PubMedCrossRef
19.
Zurück zum Zitat Maekawa, T., M. Jinnin, M. Ohtsuki, et al. 2013. Serum levels of interleukin-1alpha in patients with systemic sclerosis. Journal of Dermatology 40: 98–101.PubMedCrossRef Maekawa, T., M. Jinnin, M. Ohtsuki, et al. 2013. Serum levels of interleukin-1alpha in patients with systemic sclerosis. Journal of Dermatology 40: 98–101.PubMedCrossRef
20.
Zurück zum Zitat Andersen, G.N., K. Nilsson, O. Nagaeva, et al. 2011. Cytokine mRNA profile of alveolar T lymphocytes and macrophages in patients with systemic sclerosis suggests a local Tr1 response. Scandinavian Journal of Immunology 74: 272–281.PubMedCrossRef Andersen, G.N., K. Nilsson, O. Nagaeva, et al. 2011. Cytokine mRNA profile of alveolar T lymphocytes and macrophages in patients with systemic sclerosis suggests a local Tr1 response. Scandinavian Journal of Immunology 74: 272–281.PubMedCrossRef
21.
Zurück zum Zitat Higgins, G.C., Y. Wu, and A.E. Postlethwaite. 1999. Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1 alpha. Journal of Immunology 163: 3969–3975. Higgins, G.C., Y. Wu, and A.E. Postlethwaite. 1999. Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1 alpha. Journal of Immunology 163: 3969–3975.
22.
Zurück zum Zitat Kawaguchi, Y., M. Hara, and T.M. Wright. 1999. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. Journal of Clinical Investigation 103: 1253–1260.PubMedCentralPubMedCrossRef Kawaguchi, Y., M. Hara, and T.M. Wright. 1999. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. Journal of Clinical Investigation 103: 1253–1260.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Kawaguchi, Y., S.A. McCarthy, S.C. Watkins, et al. 2004. Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. Journal of Rheumatology 31: 1946–1954.PubMed Kawaguchi, Y., S.A. McCarthy, S.C. Watkins, et al. 2004. Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. Journal of Rheumatology 31: 1946–1954.PubMed
24.
Zurück zum Zitat Kirk, T.Z., and M.D. Mayes. 1999. IL-1 rescues scleroderma myofibroblasts from serum-starvation-induced cell death. Biochemical and Biophysical Research Communications 255: 129–132.PubMedCrossRef Kirk, T.Z., and M.D. Mayes. 1999. IL-1 rescues scleroderma myofibroblasts from serum-starvation-induced cell death. Biochemical and Biophysical Research Communications 255: 129–132.PubMedCrossRef
25.
Zurück zum Zitat Hu, B., S. Wang, Y. Zhang, et al. 2003. A nuclear target for interleukin-1alpha: interaction with the growth suppressor necdin modulates proliferation and collagen expression. Proceedings of the National Academy of Sciences of the United States of America 100: 10008–10013.PubMedCentralPubMedCrossRef Hu, B., S. Wang, Y. Zhang, et al. 2003. A nuclear target for interleukin-1alpha: interaction with the growth suppressor necdin modulates proliferation and collagen expression. Proceedings of the National Academy of Sciences of the United States of America 100: 10008–10013.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Kawaguchi, Y., E. Nishimagi, A. Tochimoto, et al. 2006. Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts. Proceedings of the National Academy of Sciences of the United States of America 103: 14501–14506.PubMedCentralPubMedCrossRef Kawaguchi, Y., E. Nishimagi, A. Tochimoto, et al. 2006. Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts. Proceedings of the National Academy of Sciences of the United States of America 103: 14501–14506.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Zamostna, B., J. Novak, V. Vopalensky, et al. 2012. N-terminal domain of nuclear IL-1alpha shows structural similarity to the C-terminal domain of Snf1 and binds to the HAT/core module of the SAGA complex. PLoS One 7: e41801.PubMedCentralPubMedCrossRef Zamostna, B., J. Novak, V. Vopalensky, et al. 2012. N-terminal domain of nuclear IL-1alpha shows structural similarity to the C-terminal domain of Snf1 and binds to the HAT/core module of the SAGA complex. PLoS One 7: e41801.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Aden, N., A. Nuttall, X. Shiwen, et al. 2010. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. Journal of Investigative Dermatology 130: 2191–2200.PubMedCrossRef Aden, N., A. Nuttall, X. Shiwen, et al. 2010. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. Journal of Investigative Dermatology 130: 2191–2200.PubMedCrossRef
29.
Zurück zum Zitat Yamamoto, T., Y. Sawada, I. Katayama, et al. 1998. Increased production of nitric oxide stimulated by interleukin-1beta in peripheral blood mononuclear cells in patients with systemic sclerosis. British Journal of Rheumatology 37: 1123–1125.PubMedCrossRef Yamamoto, T., Y. Sawada, I. Katayama, et al. 1998. Increased production of nitric oxide stimulated by interleukin-1beta in peripheral blood mononuclear cells in patients with systemic sclerosis. British Journal of Rheumatology 37: 1123–1125.PubMedCrossRef
30.
Zurück zum Zitat Kanangat, S., A.E. Postlethwaite, G.C. Higgins, and K.A. Hasty. 2006. Novel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosis. Journal of Investigative Dermatology 126: 756–765.PubMedCrossRef Kanangat, S., A.E. Postlethwaite, G.C. Higgins, and K.A. Hasty. 2006. Novel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosis. Journal of Investigative Dermatology 126: 756–765.PubMedCrossRef
31.
Zurück zum Zitat Kawaguchi, Y., A. Tochimoto, N. Ichikawa, et al. 2003. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis and Rheumatism 48: 186–192.PubMedCrossRef Kawaguchi, Y., A. Tochimoto, N. Ichikawa, et al. 2003. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis and Rheumatism 48: 186–192.PubMedCrossRef
32.
Zurück zum Zitat Kawaguchi, Y., M. Hara, N. Kamatani, et al. 2003. Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1 alpha in systemic sclerosis. Arthritis and Rheumatism 48: 193–202.PubMedCrossRef Kawaguchi, Y., M. Hara, N. Kamatani, et al. 2003. Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1 alpha in systemic sclerosis. Arthritis and Rheumatism 48: 193–202.PubMedCrossRef
33.
Zurück zum Zitat Kawaguchi, Y., A. Tochimoto, M. Hara, et al. 2007. Contribution of single nucleotide polymorphisms of the IL1A gene to the cleavage of precursor IL-1alpha and its transcription activity. Immunogenetics 59: 441–448.PubMedCrossRef Kawaguchi, Y., A. Tochimoto, M. Hara, et al. 2007. Contribution of single nucleotide polymorphisms of the IL1A gene to the cleavage of precursor IL-1alpha and its transcription activity. Immunogenetics 59: 441–448.PubMedCrossRef
34.
Zurück zum Zitat Hutyrova, B., J. Lukac, V. Bosak, et al. 2004. Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis. Journal of Rheumatology 31: 81–84.PubMed Hutyrova, B., J. Lukac, V. Bosak, et al. 2004. Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis. Journal of Rheumatology 31: 81–84.PubMed
35.
Zurück zum Zitat Beretta, L., F. Bertolotti, F. Cappiello, et al. 2007. Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung physiology. Human Immunology 68: 603–609.PubMedCrossRef Beretta, L., F. Bertolotti, F. Cappiello, et al. 2007. Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung physiology. Human Immunology 68: 603–609.PubMedCrossRef
36.
Zurück zum Zitat Beretta, L., F. Cappiello, J.H. Moore, et al. 2008. Interleukin-1 gene complex single nucleotide polymorphisms in systemic sclerosis: a further step ahead. Human Immunology 69: 187–192.PubMedCrossRef Beretta, L., F. Cappiello, J.H. Moore, et al. 2008. Interleukin-1 gene complex single nucleotide polymorphisms in systemic sclerosis: a further step ahead. Human Immunology 69: 187–192.PubMedCrossRef
37.
Zurück zum Zitat Beretta, L., F. Cappiello, J.H. Moore, et al. 2008. Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis and Rheumatism 59: 974–983.PubMedCrossRef Beretta, L., F. Cappiello, J.H. Moore, et al. 2008. Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis and Rheumatism 59: 974–983.PubMedCrossRef
38.
Zurück zum Zitat Mattuzzi, S., S. Barbi, A. Carletto, et al. 2007. Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. Journal of Rheumatology 34: 997–1004.PubMed Mattuzzi, S., S. Barbi, A. Carletto, et al. 2007. Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. Journal of Rheumatology 34: 997–1004.PubMed
39.
Zurück zum Zitat Wang, S., L. Ding, S.S. Liu, et al. 2012. IL-33: a potential therapeutic target in autoimmune diseases. Journal of Investigative Medicine 60: 1151–1156.PubMed Wang, S., L. Ding, S.S. Liu, et al. 2012. IL-33: a potential therapeutic target in autoimmune diseases. Journal of Investigative Medicine 60: 1151–1156.PubMed
40.
Zurück zum Zitat Manetti, M., L. Ibba-Manneschi, V. Liakouli, et al. 2010. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Annals of the Rheumatic Diseases 69: 598–605.PubMedCrossRef Manetti, M., L. Ibba-Manneschi, V. Liakouli, et al. 2010. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Annals of the Rheumatic Diseases 69: 598–605.PubMedCrossRef
41.
Zurück zum Zitat Manetti, M., S. Guiducci, C. Ceccarelli, et al. 2011. Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Annals of the Rheumatic Diseases 70: 1876–1878.PubMedCrossRef Manetti, M., S. Guiducci, C. Ceccarelli, et al. 2011. Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Annals of the Rheumatic Diseases 70: 1876–1878.PubMedCrossRef
42.
Zurück zum Zitat Yanaba, K., A. Yoshizaki, Y. Asano, et al. 2011. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clinical Rheumatology 30: 825–830.PubMedCrossRef Yanaba, K., A. Yoshizaki, Y. Asano, et al. 2011. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clinical Rheumatology 30: 825–830.PubMedCrossRef
43.
Zurück zum Zitat Terras, S., E. Opitz, R.K. Moritz, et al. 2013. Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis. Annals of the Rheumatic Diseases 72: 144–145.PubMedCrossRef Terras, S., E. Opitz, R.K. Moritz, et al. 2013. Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis. Annals of the Rheumatic Diseases 72: 144–145.PubMedCrossRef
44.
Zurück zum Zitat Wen, D., J. Liu, X. Du, et al. 2013. Association of interleukin-18 (−137G/C) polymorphism with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. International Reviews of Immunology. doi:10.3109/08830185.2013.816699.PubMed Wen, D., J. Liu, X. Du, et al. 2013. Association of interleukin-18 (−137G/C) polymorphism with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. International Reviews of Immunology. doi:10.​3109/​08830185.​2013.​816699.PubMed
45.
Zurück zum Zitat Pan, H.F., J. Wang, R.X. Leng, et al. 2011. Interleukin-18: friend or foe for systemic sclerosis. Journal of Investigative Dermatology 131: 2495.PubMedCrossRef Pan, H.F., J. Wang, R.X. Leng, et al. 2011. Interleukin-18: friend or foe for systemic sclerosis. Journal of Investigative Dermatology 131: 2495.PubMedCrossRef
46.
Zurück zum Zitat Tochimoto, A., E. Nishimagi, Y. Kawaguchi, et al. 2001. A case of recurrent hemophagocytic syndrome complicated with systemic sclerosis: relationship between disease activity and serum level of IL-18. Ryūmachi 41: 659–664.PubMed Tochimoto, A., E. Nishimagi, Y. Kawaguchi, et al. 2001. A case of recurrent hemophagocytic syndrome complicated with systemic sclerosis: relationship between disease activity and serum level of IL-18. Ryūmachi 41: 659–664.PubMed
47.
Zurück zum Zitat Mosaad, Y.M., S.S. Metwally, F.A. Auf, et al. 2003. Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production. The Egyptian Journal of Immunology 10: 19–26.PubMed Mosaad, Y.M., S.S. Metwally, F.A. Auf, et al. 2003. Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production. The Egyptian Journal of Immunology 10: 19–26.PubMed
48.
Zurück zum Zitat Scala, E., S. Pallotta, A. Frezzolini, et al. 2004. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clinical and Experimental Immunology 138: 540–546.PubMedCentralPubMedCrossRef Scala, E., S. Pallotta, A. Frezzolini, et al. 2004. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clinical and Experimental Immunology 138: 540–546.PubMedCentralPubMedCrossRef
49.
Zurück zum Zitat Kim, H.J., S.B. Song, J.M. Choi, et al. 2010. IL-18 downregulates collagen production in human dermal fibroblasts via the ERK pathway. Journal of Investigative Dermatology 130: 706–715.PubMedCrossRef Kim, H.J., S.B. Song, J.M. Choi, et al. 2010. IL-18 downregulates collagen production in human dermal fibroblasts via the ERK pathway. Journal of Investigative Dermatology 130: 706–715.PubMedCrossRef
50.
Zurück zum Zitat Artlett, C.M., S. Sassi-Gaha, J.L. Rieger, et al. 2011. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis and Rheumatism 63: 3563–3574.PubMedCrossRef Artlett, C.M., S. Sassi-Gaha, J.L. Rieger, et al. 2011. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis and Rheumatism 63: 3563–3574.PubMedCrossRef
52.
Zurück zum Zitat Gresnigt, MS, and F.L.van de Veerdonk. 2013. Biology of IL-36 cytokines and their role in disease. Semin Immunol (13)00155-3. Gresnigt, MS, and F.L.van de Veerdonk. 2013. Biology of IL-36 cytokines and their role in disease. Semin Immunol (13)00155-3.
53.
Zurück zum Zitat Rahman, P., S. Sun, L. Peddle, et al. 2006. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis and Rheumatism 54: 2321–2325.PubMedCrossRef Rahman, P., S. Sun, L. Peddle, et al. 2006. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis and Rheumatism 54: 2321–2325.PubMedCrossRef
54.
Zurück zum Zitat Boraschi, D., D. Lucchesi, S. Hainzl, et al. 2011. IL-37: a new anti-inflammatory cytokine of the IL-1 family. European Cytokine Network 22: 127–147.PubMed Boraschi, D., D. Lucchesi, S. Hainzl, et al. 2011. IL-37: a new anti-inflammatory cytokine of the IL-1 family. European Cytokine Network 22: 127–147.PubMed
55.
Zurück zum Zitat Song, L., F. Qiu, Y. Fan, et al. 2013. Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. Journal of Clinical Immunology 33: 111–117.PubMedCrossRef Song, L., F. Qiu, Y. Fan, et al. 2013. Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. Journal of Clinical Immunology 33: 111–117.PubMedCrossRef
Metadaten
Titel
Association of Interleukin 1 Family with Systemic Sclerosis
verfasst von
Li Zhang
Jun-Wei Yan
Yu-Jie Wang
Ya-Nan Wan
Bing-Xiang Wang
Jin-Hui Tao
Bing Chen
Bao-Zhu Li
Guo-Jun Yang
Jing Wang
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2014
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9848-7

Weitere Artikel der Ausgabe 4/2014

Inflammation 4/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.